Product development

Aduro Biotech Europe, a subsidiary of U.S.-based Aduro Biotech, is focused on the development of B-select monoclonal antibodies (mAB) for the treatment of cancer and other serious conditions. The lead B-select program is BION-1301, an anti-APRIL antibody expected to enter clinical development for the treatment of multiple myeloma in late 2017.


The B-select technology is a key component of Aduro’s ’ development pipeline, which also consists of LADD (live, attenuated double-deleted Listeria monocytogenes) and STING Pathway Activators. Collectively, Aduro’s three technology platforms are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth. To learn more, visit

Area of work

Oncology, Immunology, Antibodies, Drug development

Drug development Pipeline

Target discovery – Clinical development

``Here are facilities that are not available anywhere else. The Pivot Park Screening Centre (PPSC) is a good example of this. PPSC has a collection of more than 300,000 compounds that can serve as a starting point for new medicines. Here, as a life science entrepreneur, you can have your target screened and have your own new compounds tested. ``

News from Aduro Biotech Europe

Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma

11 Feb 19

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer

12 Jun 18

Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors

07 Mar 18